Related Experiment Video
Updated: Jun 19, 2026
07:38
Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants
Published on: June 6, 2025
Pharmacogenomics in acute myeloid leukemia
Christophe Roumier1, Meyling H Cheok
1Centre Hospitalier et Universitaire de Lille, Lille, France.
Pharmacogenomics
|November 7, 2009
Summary
Pharmacogenomics offers new hope for treating acute myeloid leukemia (AML) by identifying genetic markers to personalize therapy. This approach aims to overcome drug resistance and improve outcomes for AML patients.
Area of Science:
- Oncology
- Pharmacogenomics
- Molecular Biology
Background:
- Acute myeloid leukemia (AML) presents a significant global health challenge with generally poor prognoses.
- Existing AML classifications identify favorable subgroups, but many patients face intermediate or unfavorable outcomes, often due to drug resistance and relapse.
- There is a critical need for novel diagnostic and therapeutic strategies in AML, necessitating a deeper understanding of its molecular pathogenesis.
Purpose of the Study:
- To review the current landscape and recent advancements in pharmacogenomics as applied to acute myeloid leukemia (AML).
- To explore how understanding genetic variations can lead to improved diagnostic and therapeutic options for AML patients.
- To highlight the potential of pharmacogenomics in subclassifying AML patients and tailoring treatment intensity.
Main Methods:
- Literature review focusing on pharmacogenomics in AML.
- Analysis of genetic variations in drug-metabolizing enzymes, targets, and transporters.
- Synthesis of current research on pharmacogenomic markers and their clinical implications.
Main Results:
- Pharmacogenomics investigates how genetic variations influence drug response in AML.
- Genetic markers hold potential for functionally subcategorizing AML patients.
- These markers can inform treatment decisions, impacting therapy nature and intensity.
Conclusions:
- Pharmacogenomics is crucial for developing new therapies for AML.
- Personalized treatment strategies based on genetic profiles can potentially overcome drug resistance.
- Further research in pharmacogenomics promises to enhance AML patient outcomes.
Related Concept Videos
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
01:29Pharmacogenomics: Identification of New Drug Targets
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
01:29Pharmacogenetics and Pharmacogenomics: Overview
Pharmacogenetics and pharmacogenomics examine how genetic factors influence an individual's response to drugs. While pharmacogenetics focuses on the impact of specific genetic variants on drug effects, pharmacogenomics takes a broader approach, studying how genetic variation across populations contributes to differences in drug responses. These fields aim to explain why individuals may experience varying levels of efficacy or adverse reactions to the same medication.Variability in drug...
01:27Pharmacogenetics of Drug Metabolism: Overview
Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
01:28Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes
Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450 isoenzymes,...